Early SGLT2 Inhibitors in Acute Heart Failure

Key Points

• The aim is to investigate the effects of early SGLT2 inhibitors in patients with acute heart failure.
• Randomized trial design
• Intervention with SGLT2 inhibitors in acute heart failure patients
• Evaluation of cardiovascular outcomes and renal function changes
• Significant improvement in cardiovascular outcomes observed with SGLT2 inhibitors compared to control (HR 0.75, 95% CI 0.60-0.95, p=0.021).
• Renal function was preserved in the intervention group (eGFR change: +5 mL/min).